검색어 : 통합검색[Anderson Gillian]
총 494건 중 494건 출력
, 47/50 페이지
-
461
- Beyond 9-5: Work-Life Boundary Management in the Future of Work
- Chan-Ahuja, Stephanie; Giurge, Laura Maria; Little, Laura McAndrews; Beetz, Arianna M.; Conzon, Vanessa; Giurge, Laura Maria; Rogers, Benjamin Alan; Barsade, Sigal; Chan-Ahuja, Stephanie; DeCelles, Katherine Ann; Hershfield, Hal; Huising, Ruthanne; Ku, Gillian; Norton, Michael; Rothbard, Nancy; Sezer, Ovul; Watkins, Trevor; Zhong, Chen-Bo; London Business School; London School of Economics and Political Science; U. of Georgia; The Wharton School, U. of Pennsylvania; Boston College; London School of Economics and Political Science; UNC-Chapel Hill; The Wharton School, U. of Pennsylvania; London Business School; U. of Toronto; UCLA Anderson School of Management; EMLYON Business School; London Business School; Harvard U.; U. of Pennsylvania; Columbia Business School; U. of Oklahoma; U. of Toronto; (Academy of management annual meeting proceedings, v.2022, 2022, pp.11415)
-
462
- Population depletion activates autonomous CD154-dependent survival in biopsylike Burkitt lymphoma cells
- Challa, Anita; Eliopoulos, Aristides G.; Holder, Michelle J.; Burguete, Alondra Schweizer; Pound, John D.; Chamba, Anita; Grafton, Gillian; Armitage, Richard J.; Gregory, Christopher D.; Martinez-Valdez, Hector; Young, Lawrence; Gordon, John; From the MRC Centre for Immune Regulation and the Institute for Cancer Studies, The University of Birmingham, Birmingham, United Kingdom; School of Biomedical Sciences, The University of Nottingham, Nottingham, United Kingdom; Institute of Cell, Animal and Population Biology, University of Edinburgh, United Kingdom; Immunex Corporation, Seattle, WA; Department of Immunology, MD Anderson Cancer Center, Houston, TX.; From the MRC Centre for Immune Regulation and the Institute for Cancer Studies, The University of Birmingham, Birmingham, United Kingdom; School of Biomedical Sciences, The University of Nottingham, Nottingham, United Kingdom; Institute of Cell, Animal and Population Biology, University of Edinburgh, United Kingdom; Immunex Corporation, Seattle, WA; Department of Immunology, MD Anderson Cancer Center, Houston, TX.; From the MRC Centre for Immune Regulation and the Institute for Cancer Studies, The University of Birmingham, Birmingham, United Kingdom; School of Biomedical S; (Blood, v.99, 2002, pp.3411-3418)
-
463
- The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: A patient care evaluation study from the American College of Surgeons National Cancer Data Base
- Straughn Jr., J. Michael; Numnum Jr., T. Michael; Kilgore Jr., Larry C.; Partridge Jr., Edward E.; Phillips Jr., Jerri Linn; Markman Jr., Maurie; Thomas Jr., Gillian M.; Burke Jr., Thomas W.; ; (Gynecologic oncology, v.99, 2005, pp.530-535)
-
464
- Foundations of cumulative culture in apes: improved foraging efficiency through relinquishing and combining witnessed behaviours in chimpanzees ( <i>Pan troglodytes</i> )
-
Davis, Sarah J.;
Vale, Gillian L.;
Schapiro, Steven J.;
Lambeth, Susan P.;
Whiten, Andrew;
Centre for Social learning and Cognitive Evolution, School of Psychology & Neuroscience, University of St Andrews , St Andrews, KY16 9JP, Scotland;
Centre for Social learning and Cognitive Evolution, School of Psychology & Neuroscience, University of St Andrews , St Andrews, KY16 9JP, Scotland;
National Center for Chimpanzee Care, Department of Veterinary Sciences, Michale E. Keeling Center for Comparative Medicine and Research, the University of Texas MD Anderson Cancer Center , Bastrop, TX 78602, USA;
National Center for Chimpanzee Care, Department of Veterinary Sciences, Michale E. Keeling Center for Comparative Medicine and Research, the University of Texas MD Anderson Cancer Center , Bastrop, TX 78602, USA;
Centre for Social learning and Cognitive Evolution, School of Psychology & Neuroscience, University of St Andrews , St Andrews, KY16 9JP, Scotland
Scotland
-
465
- Abstract PO5-19-04: EVOLVE: An Ambispective, Patient-Centered, Real-World Early-Stage Breast Cancer Study in the United States
- Friedler, Haley; Tierney, Meghan; Baker, Melinda; Hanson, Gillian; Briceno, Josefa; Smith, Karen; Baber, Michele; Glover, Kara; Xu, Xiaoqing; Ryan, Kellie; Segunmaru, Zulikhat; Lam, Clara; Lustberg, Maryam; Henry, N. Lynn; Greenup, Rachel; Chavez, Marianna; Unger, Joseph; Ho, Alice; Collyar, Deborah; 1PicnicHealth; ; 1PicnicHealth; ; 1PicnicHealth; ; 1PicnicHealth; ; 2AstraZeneca; ; 3Johns Hopkins University School of Medicine; ; 2AstraZeneca; ; 2AstraZeneca; ; 2AstraZeneca; ; 2AstraZeneca; ; 2AstraZeneca; ; 4AstraZeneca, Maryland, United States; ; 5Yale Cancer Center, New Haven, Connecticut, United States; ; 6University of Michigan Medical School; ; 7Yale School of Medicine, New Haven, Connecticut, United States; ; 8UT MD Anderson Cancer Center, Houston, Texas, United States; ; 9Fred Hutchinson Cancer Center; ; 10Duke Cancer Center; ; 11Patient Advocates in Research; (Cancer research : the official organ of the American Association for Cancer Research, Inc, v.84, 2024, pp.PO5-19-04-PO5-19-04)
-
466
- Abstract 859: Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer
- Wolf, Denise M.; Yau, Christina; Brown-Swigart, Lamorna; Hirst, Gillian; Buxton, Meredith; Paoloni, Melissa; Olopade, Olufunmilayo; De Michele, Angela; Symmans, Fraser; Rugo, Hope; Berry, Don; Esserman, Laura; van ‘t Veer, Laura; University of California, San Francisco, CA; ; University of California, San Francisco, CA; ; University of California, San Francisco, CA; ; University of California, San Francisco, CA; ; University of California, San Francisco, CA; ; QuantumLeap Healthcare Collaborative, San Francisco, CA; ; University of Chicago, Chicago, IL; ; University of Pennsylvania, Philadelphia, PA; ; University of Texas, MD Anderson, Houston, TX; ; University of California, San Francisco, CA; ; Berry Consultants, LLC, Austin, TX.; University of California, San Francisco, CA; ; University of California, San Francisco, CA; (Cancer research : the official organ of the American Association for Cancer Research, Inc, v.76, 2016, pp.859-859)
-
467
- Protein activation mapping and exploratory predictive markers for pCR in triple-negative breast cancer patients treated with neratinib in the I-SPY 2 TRIAL.
- Wulfkuhle, Julia Dianne; Yau, Christina; Wolf, Denise M; Gallagher, Rosa Isela; Deng, Jianghong; Brown Swigart, Lamorna; Hirst, Gillian; Liu, Minetta C.; Park, John W.; Esserman, Laura; Berry, Donald A.; van't Veer, Laura; Petricoin, Emanuel; George Mason Univ, Columbia, MD; Buck Institute for Age Research, Novato, CA; UC San Francisco, San Francisco, CA; George Mason University, Manassas, VA; George Mason University, Manassas, VA; UC San Francisco, San Francisco, CA; UC San Francisco, San Francisco, CA; Mayo Clinic, Rochester, MN; UC San Francisco, San Francisco, CA; UC San Francisco, San Francisco, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Francisco, San Francisco, CA; George Mason University, Manassas, VA; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.33, 2015, pp.1085-1085)
-
468
- Abstract 858: Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL
- Wolf, Denise M.; Yau, Christina; Sanil, Ashish; Brown-Swigart, Lamorna; Hirst, Gillian; Buxton, Meredith; Paoloni, Melissa; Olopade, Olufunmilayo; Rugo, Hope; De Michele, Angela; Symmans, Fraser; Berry, Don; Esserman, Laura; van ‘t Veer, Laura; University of California, San Francisco, CA; ; University of California, San Francisco, CA; ; Berry Consultants, LLC, Austin, TX; ; University of California, San Francisco, CA; ; University of California, San Francisco, CA; ; University of California, San Francisco, CA; ; QuantumLeap Healthcare Collaborative, San Francisco, CA; ; University of Chicago, Chicago, IL; ; University of California, San Francisco, CA; ; University of Pennsylvania, Philadelphia, PA; ; University of Texas, MD Anderson, Houston, TX.; Berry Consultants, LLC, Austin, TX; ; University of California, San Francisco, CA; ; University of California, San Francisco, CA; (Cancer research : the official organ of the American Association for Cancer Research, Inc, v.76, 2016, pp.858-858)
-
469
- Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
- Leon-Ferre, Roberto Antonio; Dimitroff, Katrina; Yau, Christina; Giridhar, Karthik; Mukhtar, Rita A.; Hirst, Gillian L.; Hylton, Nola; Symmans, W. Fraser Fraser; Goetz, Matthew P.; Esserman, Laura; Boughey, Judy Caroline; Mayo Clinic, Rochester, MN; University of California, San Francisco, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Mayo Clinic, Rochester, MN; University of California, San Francisco, San Francisco, CA; UCSF Comprehensive Cancer Center, San Francisco, CA; University of California, San Francisco, San Francisco, CA; The University of Texas MD Anderson Cancer Center, Alliance for Clinical Trials in Oncology, Houston, TX; Mayo Clinic, Rochester, MN; Department of Surgery, University of California, San Francisco, San Francisco, CA; Mayo Clinic, Rochester, MN; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.42, 2024, pp.594-594)
-
470
- Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial.
- Wulfkuhle, Julia Dianne; Yau, Christina; Wolf, Denise M.; Gallagher, Rosa Isela; Brown Swigart, Lamorna; Hirst, Gillian L.; Campbell, Michael; Nanda, Rita; Liu, Minetta C.; Pusztai, Lajos; Esserman, Laura; Berry, Donald A.; van 't Veer, Laura; Petricoin, Emanuel; George Mason Univ, Columbia, MD; ; Buck Institute for Age Research, Novato, CA; ; UC San Francisco, San Francisco, CA; ; George Mason University, Manassas, VA; ; UC San Francisco, San Francisco, CA; ; UC San Francisco, San Francisco, CA; ; UCSF, San Francisco, CA; ; The University of Chicago, Chicago, IL; ; Mayo Clinic, Rochester, MN; ; Yale Cancer Center, New Haven, CT; ; University of California San Francisco, San Francisco, CA; ; The University of Texas MD Anderson Cancer Center, Houston, TX; ; University of California San Francisco, San Francsico, CA; ; Perthera, Inc., Mclean, VA; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.37, 2019, pp.2631-2631)
QUICK MENU
